Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content
Developers plan to discuss findings from the phase 2/3 GBM AGILE study with the FDA to determine a potential approval pathway for paxalisib.

Paxalisib Improves Survival Vs SOC in Newly Diagnosed Glioblastoma

Russ Conroy
July 11th 2024
Article

Developers plan to discuss findings from the phase 2/3 GBM AGILE study with the FDA to determine a potential approval pathway for paxalisib.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.

TTFields Combo Prolongs Time to Progression in NSCLC Brain Metastasis Group

Jordyn Sava
June 6th 2024
Article

Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

Timothy Chen, MD
April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

Petosemtamab Combo Shows Responses, Tolerability in Head and Neck Cancer

Kristi Rosa
June 5th 2024
Article

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

Most treatment-related adverse effects reported with CAN-2409 plus valacyclovir in a phase 2 trial were grade 1 or 2.

Novel Adenovirus Combo Elicits Immune Responses in Stage III/IV NSCLC

Tony Berberabe, MPH
June 4th 2024
Article

Most treatment-related adverse effects reported with CAN-2409 plus valacyclovir in a phase 2 trial were grade 1 or 2.